Abdülkadir Koçanoğlu, Yakup Düzköprü, Esra Zeynelgil, Nesrin Gürçay, Serdar Karakaya, Doğan Yazılıtaş
Acta Haematologica Oncologica Turcica - 2025;58(3):240-244
Aim: Treatment guidelines for thymic carcinoma, a rare cancer involving multiple clinical subgroups, are primarily derived from retrospective studies. We aimed to evaluate the frequency of histopathological subgroups, treatment modalities, clinicopathological characteristics, and to assess their correlation with the odds of survival of patients with thymic cancer. Methods: A retrospective analysis was performed on data from 19 individuals monitored in outpatient oncology clinics following diagnosis of thymic carcinoma. Surgical history, margin status, sites of recurrence or metastasis, date of final follow-up, and date of death were among the clinical and demographic factors recorded and examined. Results: For the whole group, the median overall survival (OS) was 20 months [95% confidence interval (CI): 2.25-37.75]. The median OS was ten months for individuals who were not operated on (95% CI: 7.43-12.56), compared with 68 months for operated patients (95% CI: 16.67-119.32) (p=0.010). The median OS for patients receiving mediastinal radiation was 68 months (95% CI: 15.67-120.32), compared with 8 months (95% CI: 3.19-12.80) for those not receiving RT. Although the difference did not reach statistical significance (p=0.064), patients with stage IV disease had a median OS of 14 months (95% CI: 6.45-21.55), whereas patients without stage IV disease had a median OS of 68 months (95% CI: 22.18-113.83). Conclusion: Consistent with our findings, postoperative radiotherapy and surgical excision seem to be the most significant prognostic factors. Surgical options-including upfront surgery-and postoperative radiotherapy should be seriously considered in the treatment of thymic carcinoma.
